Leerink Partnrs Issues Positive Estimate for RARE Earnings

Key Points

• Analysts at Leerink Partners have increased their Q3 2025 earnings per share estimate for Ultragenyx Pharmaceutical to ($1.31), up from the previous estimate of ($1.39).
• Ultragenyx's stock has a current market cap of $2.63 billion, with shares opening at $27.83, down 0.8% recently.
• There is a general consensus among analysts with a "Moderate Buy" average rating and a price target of $82.17 for Ultragenyx shares, despite some firms reducing their target prices.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Tuesday, August 5th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($1.31) per share for the quarter, up from their prior estimate of ($1.39). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($5.20) EPS and FY2026 earnings at ($4.58) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The firm's revenue was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.52) earnings per share.

A number of other equities research analysts have also recently issued reports on RARE. Canaccord Genuity Group decreased their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research report on Friday. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a research report on Monday, July 28th. Wells Fargo & Company decreased their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Finally, Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Trading Down 1.0%

Ultragenyx Pharmaceutical stock traded down $0.29 during trading hours on Friday, reaching $27.54. 1,527,932 shares of the company were exchanged, compared to its average volume of 2,814,751. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -4.98 and a beta of 0.25. The stock has a 50-day moving average of $33.32 and a 200 day moving average of $36.73. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $60.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning bought a new position in Ultragenyx Pharmaceutical in the second quarter worth $454,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 34,592 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 2,458 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock valued at $62,291,000 after acquiring an additional 66,394 shares during the period. S&CO Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 24.7% during the second quarter. S&CO Inc. now owns 25,255 shares of the biopharmaceutical company's stock valued at $918,000 after acquiring an additional 5,000 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at $309,000. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.